BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Bought by Prudential Financial Inc.

Prudential Financial Inc. grew its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 10.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 983,033 shares of the biotechnology company's stock after purchasing an additional 90,603 shares during the period. Prudential Financial Inc. owned approximately 0.47% of BioCryst Pharmaceuticals worth $7,392,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the company. Venturi Wealth Management LLC purchased a new stake in BioCryst Pharmaceuticals during the fourth quarter worth approximately $46,000. R Squared Ltd purchased a new stake in BioCryst Pharmaceuticals during the 4th quarter worth $48,000. KBC Group NV increased its holdings in BioCryst Pharmaceuticals by 80.1% in the 4th quarter. KBC Group NV now owns 10,198 shares of the biotechnology company's stock valued at $77,000 after purchasing an additional 4,537 shares in the last quarter. Raymond James Financial Inc. purchased a new position in BioCryst Pharmaceuticals in the fourth quarter valued at about $80,000. Finally, Quantinno Capital Management LP purchased a new position in BioCryst Pharmaceuticals in the third quarter valued at about $82,000. Hedge funds and other institutional investors own 85.88% of the company's stock.

BioCryst Pharmaceuticals Stock Down 4.6 %

Shares of NASDAQ:BCRX traded down $0.36 during trading on Monday, hitting $7.50. 2,216,032 shares of the company traded hands, compared to its average volume of 2,789,809. BioCryst Pharmaceuticals, Inc. has a one year low of $4.03 and a one year high of $9.50. The stock has a market capitalization of $1.57 billion, a price-to-earnings ratio of -12.29 and a beta of 1.85. The business's fifty day moving average is $8.18 and its 200-day moving average is $7.82.

Remove Ads

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.06). The business had revenue of $131.50 million during the quarter, compared to analysts' expectations of $126.64 million. The business's quarterly revenue was up 40.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.28 earnings per share. On average, analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current year.

Analyst Upgrades and Downgrades

BCRX has been the topic of several analyst reports. Royal Bank of Canada reiterated an "outperform" rating and set a $11.00 target price (up from $10.00) on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. Wedbush initiated coverage on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They issued an "outperform" rating and a $15.00 price objective on the stock. HC Wainwright reaffirmed a "buy" rating and set a $30.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. Evercore ISI raised their price objective on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an "outperform" rating in a research note on Monday, January 13th. Finally, JMP Securities restated a "market outperform" rating and set a $18.00 price objective on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, BioCryst Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $15.57.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.